Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | 127,199 | 81,732 |
| Operating expenses: | ||
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s R&D?
- Travere Therapeutics, Inc. (TVTX) reported R&D of $57.09M in Q1 2026.
- How has Travere Therapeutics, Inc.'s R&D changed year-over-year?
- Travere Therapeutics, Inc.'s R&D increased by 21.8% year-over-year, from $46.89M to $57.09M.
- What is the long-term trend for Travere Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s R&D has grown at a 0.6% compound annual growth rate (CAGR), from $201.16M to $206.01M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Travere Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude